Estimating per-infection cost and burden for dengue and Zika as a function of antibody-dependent enhancement
Table 4
Parameters representing subtype-level average costs (in 2024 USD) for each case type (d1, d2, z2) with various characteristics or outcomes. Self-managed cases include asymptomatic; ambulatory cases seek treatment; severe nonfatal involve DHF/DSS. See Results section for further detail.